What topics does this cannabis study cover?

This study covers research on: Epilepsy.

Where was this research published?

Published in Epilepsia on September 28, 2026.

Frequent cannabis use linked to greater seizure burden in epilepsy

Q: What did this research study find?

Frequent cannabis use was associated with **higher annualized focal to bilateral tonic-clonic seizure frequency** in this cohort.

Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy.

Epilepsia • September 28, 2026 • Highly Relevant

🤖

AI Summary

This retrospective cohort study asked whether frequent cannabis use was associated with epilepsy severity in adults with drug-resistant epilepsy admitted to a tertiary epilepsy monitoring unit. It compared 22 frequent users—defined as use on at least 20 days per month—with 42 nonusers; people with low cannabis use were excluded. The primary outcomes were markers of seizure burden and treatment needs.

Frequent use was associated with more frequent focal to bilateral tonic-clonic seizures, a higher prevalence of these seizures, and greater antiseizure medication burden. Frequent users also had a shorter interval from epilepsy onset to specialized monitoring. All frequent users had temporal lobe epilepsy, but the between-group difference in its prevalence was not statistically significant, and imaging analyses showed no significant group differences. Because this was a small, retrospective observational study using medical-record documentation of cannabis use, it cannot establish that cannabis caused greater epilepsy severity; prospective studies with objective exposure measures are needed. This is an abstract-based summary, not a review of the full paper.

💡 Key Findings

Frequent cannabis use was associated with higher annualized focal to bilateral tonic-clonic seizure frequency in this cohort.

Good

70%

Frequent users had a higher prevalence of focal to bilateral tonic-clonic seizures and greater antiseizure medication burden than nonusers.

Good

70%

Frequent users had a shorter time from epilepsy onset to EMU admission; imaging analyses found no significant group differences.

Good

70%

The retrospective observational findings show an association, not evidence that cannabis use caused more severe epilepsy; the authors call for prospective studies using objective exposure measures.

High

90%

📄 Original Abstract

OBJECTIVE: Cannabis use has increased substantially, with modern products characterized by high tetrahydrocannabinol concentrations and variable composition. The relationship between frequent cannabis use and epilepsy outcomes remains uncertain. We examined the association between frequent cannabis use and epilepsy severity, clinical phenotype, and imaging characteristics in patients admitted to an epilepsy monitoring unit (EMU). METHODS: This retrospective cohort study included adults with drug-resistant epilepsy admitted to a tertiary care EMU. Patients were classified based on cannabis use documented in the electronic medical record over the year prior to admission. Frequent use was defined as cannabis use on ≥20 days/month; patients with low use were excluded. Primary outcomes included markers of epilepsy severity, including time from epilepsy onset to EMU admission, presence and frequency of focal to bilateral tonic-clonic seizures (FBTCS), and antiseizure medication (ASM) burden. Secondary analyses evaluated epilepsy syndrome and mesial temporal lobe volumetric measures. RESULTS: Sixty-four patients were included (42 nonusers and 22 frequent users). Frequent cannabis use was associated with shorter time from epilepsy onset to EMU admission (mean [SD] = 5.0 [4.2] vs. 18.1 [16.3] years, p = .004), higher prevalence of FBTCS (90.9% vs. 57.1%, p = .04), greater annualized FBTCS frequency (mean [SD] = 3.00 [3.63] vs. 1.32 [3.87], p = .003), and higher ASM burden (mean [SD] = 3.05 [1.00] vs. 2.21 [1.14], p = .027). All frequent cannabis users had temporal lobe epilepsy (TLE), although the between-group difference in TLE prevalence was not statistically significant. No significant group differences were observed in imaging analysis. SIGNIFICANCE: In this cohort of patients with drug-resistant epilepsy, frequent cannabis use was associated with markers of increased epilepsy severity, including higher FBTCS burden, shorter time to specialized EMU evaluation, and greater ASM requirements. Prospective studies using objective cannabis exposure measures are needed to clarify the relationship between cannabis use and epilepsy outcomes.

Paper Type

📄 Research

Publication

Journal: Epilepsia
Published: September 28, 2026
PMID: 42803888
DOI: 10.1002/epi.70456

Authors (17)

Santiago Philibert-Rosas Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Kaitlin A Guston Department of Neurology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Mariel Kalkach-Aparicio Department of Neurology, University of South Dakota-Sanford Medical Center, Sioux Falls, South Dakota, USA.
Abigail Keller Department of Neurology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Sanaa Semia Department of Neurology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
+12 more authors